scholarly journals Update of P2Y receptor pharmacology: IUPHAR Review 27

2020 ◽  
Vol 177 (11) ◽  
pp. 2413-2433 ◽  
Author(s):  
Kenneth A. Jacobson ◽  
Esmerilda G. Delicado ◽  
Christian Gachet ◽  
Charles Kennedy ◽  
Ivar Kügelgen ◽  
...  
Keyword(s):  
P2y Receptor ◽  
Receptor Pharmacology

Cholecystokinin receptors

1995 ◽  
Vol 269 (5) ◽  
pp. G628-G646 ◽  
Author(s):  
S. A. Wank
Keyword(s):  
Function Analysis ◽  
Receptor Gene ◽  
Wide Distribution ◽  
Receptor Expression ◽  
Receptor Subtypes ◽  
Cck Receptors ◽  
High Affinity ◽  
Recombinant Receptor ◽  
Receptor Pharmacology ◽  
Specific Variation

The cholecystokinin (CCK) and gastrin families of peptides act as hormones and neuropeptides on central and peripheral CCK receptors to mediate secretion and motility in the gastrointestinal (GI) tract in the physiological response to a normal meal. CCK and its receptors are also widely distributed in the central nervous system (CNS) and contribute to the regulation of satiety, anxiety, analgesia, and dopamine-mediated behavior. Although the wide distribution, myriad number of functions, and reported pharmacological heterogeneity of CCK receptors would suggest a large number of receptor subtypes, the application of modern molecular biological techniques has identified two CCK receptors, CCK-A receptor (CCK-AR) and CCK-B receptor (CCK-BR), that mediate the actions of CCK and gastrin; gastrin receptors have been found to be identical to CCK-BR. CCK-AR, found predominantly in the GI system and select areas of the CNS, have high affinity for CCK and the nonpeptide antagonist L-364,718, whereas CCK-BR, found predominantly in the CNS and select areas of the GI system, have high affinity for CCK and gastrin and the nonpeptide antagonist L-365,260. Both CCK-AR and CCK-BR are highly conserved between species, although there is some tissue-specific variation in expression. Recombinant receptor expression faithfully reproduces the native receptor pharmacology and signal transduction pathways, allowing direct comparisons of receptor function between species as well as serving as a convenient source of receptor. Our present knowledge of the chromosomal localization, receptor gene structure, and primary sequence will allow further studies in disease association, receptor regulation, and structure-function analysis.

scholarly journals Enhanced Transport and Permeation of a Polymeric Nanocarrier across the Retina by Mixing with ATP upon Intravitreal Injection

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 463
Author(s):  
Kiyoon Kwon ◽  
Youngmin Hwang ◽  
Junyoung Jung ◽  
Giyoong Tae
Keyword(s):  
Great Increase ◽  
Pigment Epithelium ◽  
Outer Part ◽  
Vitreous Humor ◽  
Retinal Diseases ◽  
P2y Receptor ◽  
Main Site ◽  
Tight Junction Disruption ◽  
Polymeric Nanocarrier ◽  
Retina Pigment Epithelium

The outer part of the retina pigment epithelium (RPE) in the retina is the main site of neovascularization associated with retinal diseases. However, various obstacles interrupt the delivery of medicines across the RPE, mainly due to the well-developed tight junctions in the RPE. Currently, there is no practical formulation to overcome this issue. In this study, we demonstrated that simple mixing with adenosine tetraphosphate (ATP) has the potential to greatly enhance the transport and permeation of a polymeric nanocarrier across the retina via intravitreal administration. Chitosan-functionalized, pluronic-based nanocarrier (NC), which can deliver various biomolecules efficiently, was used as a polymeric nanocarrier. Mixing with ATP facilitated the diffusion of the nanocarrier in the vitreous humor by reducing the electrostatic interaction between NC and negatively charged glycosaminoglycans (GAGs) in the vitreous humor. Mixing with ATP also allowed the penetration of NC across the whole retina, and it resulted in a great increase (approximately nine times) in the transport of NC across the retina, as well as spreading it throughout the whole retina upon intravitreal administration in a mouse model. This enhanced permeation across the retina was specific to ATP but not to GTP, suggesting the possibility of P2Y receptor-mediated tight junction disruption by ATP.

GABAA receptor pharmacology

1996 ◽  
Vol 69 (3) ◽  
pp. 173-198 ◽  
Author(s):  
G.A.R. Johnston
Keyword(s):  
Gabaa Receptor ◽  
Receptor Pharmacology

Antagonism of endogenous putative P2Y receptors reduces the growth of MDCK-derived cysts cultured in vitro

2007 ◽  
Vol 292 (1) ◽  
pp. F15-F25 ◽  
Author(s):  
Clare M. Turner ◽  
Brian F. King ◽  
Kaila S. Srai ◽  
Robert J. Unwin
Keyword(s):  
Therapeutic Potential ◽  
Cyst Formation ◽  
P2y Receptors ◽  
P2x Receptor ◽  
P2y Receptor ◽  
Cyst Size ◽  
Reactive Blue 2 ◽  
Cyst Growth

P2Y receptors couple to G proteins and either mobilize intracellular Ca2+ or alter cAMP levels to modulate the activity of Ca2+- and cAMP-sensitive ion channels. We hypothesize that increased ion transport into the lumen of MDCK cysts can osmotically drive fluid movement and increase cyst size. Furthermore, activation of the adenylate cyclase/cAMP pathway may trigger cell proliferation via an extracellular signal-related kinase cascade. To test this hypothesis, several P2Y receptor inhibitors were used on the MDCK in vitro model of renal cyst formation. The nonspecific P2 receptor inhibitors reactive blue 2 and suramin reduced cyst growth significantly, as did PPADS and, to a lesser extent, the P2Y1-specific antagonist MRS2179. Cyst growth was reduced by ∼50% when ATP was removed from the culture medium with apyrase, although stable analogs of ATP failed to increase cyst size. The nonselective P2X receptor inhibitor Coomassie brilliant blue G was ineffective at reducing cyst growth, suggesting no involvement of P2X receptors. Finally, the presence of selective inhibitors of ERK activation (either PD98059 or U0126) greatly reduced cyst growth, whereas in untreated cysts ERK activity was observed to increase with time. We conclude that stimulation of endogenous P2Y receptors by extracellular ATP increases growth of MDCK cysts via cAMP-dependent activation of the ERK pathway. P2Y receptor antagonists may have therapeutic potential in reducing cyst size and slowing disease progression; although further studies in vitro and in vivo are needed to investigate the specificity and role of these P2Y receptors in renal cystic diseases.

Peptidases and smooth muscle cell angiotensin II receptor pharmacology

Peptides ◽  
1993 ◽  
Vol 14 (2) ◽  
pp. 345-352 ◽  
Author(s):  
Robert B. Cohen ◽  
Maria L. Webb ◽  
Kenneth E.J. Dickinson
Keyword(s):  
Smooth Muscle ◽  
Angiotensin Ii ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Angiotensin Ii Receptor ◽  
Receptor Pharmacology
Sign in / Sign up

Export Citation Format

Share Document